Lumenis Launches OptiLIFT to Address Lower Lid Laxity and Impaired Blinking

Lumenis Be. Ltd., a global leader in energy-based medical devices for eye care and aesthetics, has announced the launch of OptiLIFT, a breakthrough device designed to improve lower lid laxity and impaired blinking. Utilizing Dynamic Muscle Stimulation technology (DMSt), OptiLIFT tones facial muscles, offering a non-surgical alternative for addressing these common age-related concerns.

This marks a significant advancement in periocular treatments, providing a non-invasive solution for conditions that previously required surgery.

Closing the Gap in Non-Surgical Eye Care Solutions

Itay Mayer, Chief Commercial Officer of Lumenis, emphasized the clinical and commercial impact of OptiLIFT:

“OptiLIFT enables providers to address lower lid laxity and impaired blinking non-surgically, delivering meaningful results for patients while offering a unique opportunity for practice differentiation. We look forward to collaborating with providers to close the gap in their practices, bring this new solution to the market, and elevate patient care.”

Understanding Lower Lid Laxity and Impaired Blinking

Lower lid laxity is a common age-related condition caused by the weakening of the orbicularis oculi muscle, which supports eyelid structure and function. As these periorbital muscles lose tone, eyelid support diminishes, leading to laxity and impaired blinking.

Research indicates that over 60% of dry eye patients suffer from impaired lid closure, further emphasizing the need for effective, non-invasive solutions.

How OptiLIFT Works: Dynamic Muscle Stimulation & Radiofrequency

OptiLIFT employs Dynamic Muscle Stimulation technology (DMSt) to activate periorbital muscles using electrical impulses, promoting muscle tightening and improved tone.

The device also features an integrated radiofrequency component, which:

       • Delivers targeted heat to deeper skin layers.

       • Enhances collagen formation, supporting skin structure.

Additionally, OptiLIFT offers an optional micro-needling upgrade, incorporating ultra-thin needles and a double radiofrequency mechanism for enhanced treatment benefits.

Clinical Study Confirms Significant Improvements

A recent clinical study, led by James Chelnis, MD, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye, demonstrated significant improvements in lower lid function with OptiLIFT:

       • 75% reduction in lid laxity.

       • 70% improvement in blinking quality.

       • 286% increase in tear break-up time (TBUT), indicating better ocular surface hydration.

Dr. Chelnis highlighted the transformative nature of OptiLIFT:

“OptiLIFT finally offers us a non-surgical solution that is effective and comfortable for patients, without any downtime. Our clinical study revealed remarkable outcomes for patients that highlight the true value of OptiLIFT.”

Upcoming Exhibition at Vision Expo East

Lumenis will showcase OptiLIFT at Vision Expo East in Orlando, Florida, later this month, providing eye care professionals with an opportunity to explore this innovative non-invasive treatment for eyelid health.

Conclusion

The launch of OptiLIFT marks a major advancement in ophthalmic and aesthetic care, addressing lower lid laxity and impaired blinking without surgery. With its proven clinical efficacy and non-invasive approach, OptiLIFT represents a transformative solution for patients and providers seeking effective alternatives to traditional surgical interventions.